Oncology Clinical Trials in Fort Worth, TX

As of July 2026, 80 paid clinical trials are recruiting for Oncology in Fort Worth, Texas. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

80 clinical trials for Oncology

·Clear filters·↓ Download CSV

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for Metastatic Breast Cancer

20 locations incl. Gilbert

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05894239·Phase 3·Recruiting

Apply to this trial

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

for ER+, HER 2- Breast Cancer

11 locations incl. Plantation

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18 - 99

Code: NCT07540572·Phase 1·Recruiting

Apply to this trial

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

9 locations incl. Mobile

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218341·Phase 4·Recruiting

Apply to this trial

First In Human Study of CX-2051 in Advanced Solid Tumors

for Solid Tumor, Adult

8 locations incl. Denver

Sponsor: CytomX Therapeutics

Sex: All·Age: 18+

Code: NCT06265688·Phase 1·Recruiting

Apply to this trial

IKS014 in Advanced Solid Tumors That Express HER2

for Breast Cancer

4 locations incl. Newport Beach

Sponsor: Iksuda Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT05872295·Phase 1·Recruiting

Apply to this trial

First In Human Study of CX-801 in Advanced Solid Tumors

for Solid Tumor, Adult

4 locations incl. Englewood

Sponsor: CytomX Therapeutics

Sex: All·Age: 18+

Code: NCT06462794·Phase 1·Recruiting

Apply to this trial

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

for Solid Tumor

3 locations incl. Los Angeles

Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT07517198·Phase 1·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

Drug: Bevacizumab

658 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting

Apply to this trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for Biochemically Recurrent Prostate Carcinoma

Drug: Apalutamide

342 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male·Age: 18+

Code: NCT04423211·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

323 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

387 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting

Apply to this trial

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

for Cervical Cancer

134 locations incl. Goodyear

Sponsor: GOG Foundation

Sex: Female·Age: 18+

Code: NCT04831580·Recruiting

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

190 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting

Apply to this trial

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

for Non Small Cell Lung Cancer

Drug: Osimertinib

146 locations incl. Birmingham

Sponsor: PrECOG, LLC.

Sex: All·Age: 18+

Code: NCT06538038·Recruiting

Apply to this trial

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

for Hematologic Malignancies

142 locations incl. Birmingham

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: All ages

Code: NCT01351545·Recruiting

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

245 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

203 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

185 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

164 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting

Apply to this trial

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

for Metastatic Malignant Neoplasm in the Lung

219 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT05235165·Phase 3·Recruiting

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

152 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

for Hematopoietic and Lymphatic System Neoplasm

76 locations incl. Mesa

Sponsor: Children's Oncology Group

Sex: All·Age: 15 - 20

Code: NCT06410209·Phase 2·Recruiting

Apply to this trial

The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.

for Cancer

8 locations incl. College Station

Sponsor: Baylor Research Institute

Sex: All·Age: 18+

Code: NCT05371756·Recruiting

Apply to this trial

Childhood Cancer Survivor Study

for Cancer

30 locations incl. Birmingham

Sponsor: St. Jude Children's Research Hospital

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT01120353·Recruiting

Apply to this trial

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

for Hodgkin Lymphoma in Remission

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT01790152·Recruiting

Apply to this trial

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

for Neuroblastoma

Drug: Irinotecan

13 locations incl. Los Angeles

Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Sex: All·Age: 1 - 31

Code: NCT06450041·Phase 2·Recruiting

Apply to this trial

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

for Refractory Acute Myeloid Leukemia

Drug: Venetoclax

10 locations incl. San Diego

Sponsor: St. Jude Children's Research Hospital

Sex: All·Age: 1 - 30

Code: NCT06177067·Phase 1·Recruiting

Apply to this trial

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

for Rhabdomyosarcoma

Drug: Irinotecan

3 locations incl. Palo Alto

Sponsor: St. Jude Children's Research Hospital

Sex: All·Age: Up to 22

Code: NCT06023641·Phase 2·Recruiting

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

51 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting

Apply to this trial

Neuroblastoma Biology Study

for Neuroblastoma

16 locations incl. Los Angeles

Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Sex: All·Age: 31 Days - 99

Code: NCT01587300·Recruiting

Apply to this trial

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

for Hematologic Malignancy

29 locations incl. Los Angeles

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Sex: All·Age: 1 - 21

Code: NCT05476770·Phase 1·Recruiting

Apply to this trial

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

for Wilms Tumor

Drug: Selinexor

16 locations incl. Los Angeles

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 12 Months+

Code: NCT05985161·Phase 2·Recruiting

Apply to this trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

for Colorectal Cancer

5 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07659795·Phase 2·Recruiting·Listed Jun 22, 2026

Apply to this trial

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

for Endometrial Cancer

Drug: Rilvegostomig

60 locations incl. Tucson

Sponsor: AstraZeneca

Sex: Female·Age: 18+

Code: NCT06989112·Phase 3·Recruiting

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

75 locations incl. Tucson

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting

Apply to this trial

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

for Biliary Tract Cancer

Drug: Rilvegostomig

48 locations incl. Scottsdale

Sponsor: AstraZeneca

Sex: All·Age: 18 - 99

Code: NCT06467357·Phase 3·Recruiting

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

63 locations incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting

Apply to this trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

for Breast Cancer

Drug: Durvalumab

64 locations incl. Daphne

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06103864·Phase 3·Recruiting

Apply to this trial

Conditions in Oncology (Fort Worth, TX)

Non-small cell lung cancer (NSCLC)· 16 Solid tumor· 12 Breast cancer· 9 Endometrial cancer· 7 Ovarian cancer· 6 Cancer (any)· 6 Gastric cancer· 5 Hematologic malignancy· 5 Neuroblastoma· 5 Fallopian tube cancer· 4 Acute myeloid leukemia (AML)· 4 Colorectal cancer· 3 Pancreatic cancer· 3 Prostate cancer· 3 Leukemia (other)· 3 Mesothelioma· 3 Metastatic breast cancer· 2 Triple-negative breast cancer· 2 Biliary tract cancer· 2 Kidney cancer· 2 Cervical cancer· 2 Chronic lymphocytic leukemia (CLL)· 2 Myelodysplastic syndromes (MDS)· 2 Hodgkin lymphoma· 2 Non-Hodgkin lymphoma· 2 Small lymphocytic lymphoma· 2 Osteosarcoma· 2 Lung cancer· 1 Gastroesophageal junction cancer· 1 Liver cancer· 1 Bladder cancer· 1 Uterine cancer· 1 Acute lymphoblastic leukemia· 1 Myeloproliferative neoplasm· 1 Diffuse large B-cell lymphoma (DLBCL)· 1 Follicular lymphoma· 1 Melanoma· 1 Head and neck cancer· 1 Rhabdomyosarcoma· 1